This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Pollogen Ltd.
The MaximusMED system is a superior anti-aging and body contouring aesthetic break-through that facilitates treatment of all four tissue layers, using three unique technologies housed in a single platform. Clinically proven MaximusMED delivers safe and effective wrinkle reduction, skin tightening, cellulite treatment, localized fat reduction and more.
(PRWEB) February 05, 2013
Pollogen Ltd., a global leader in the medical aesthetics market and HV Comércio.Imp.Exp.Ltda announced today that Pollogen’s MaximusMED Platform has recently received ANVISA Medical Device Registration and Approval in Brazil.
The MaximusMED platform delivers a unique aesthetic procedure that allows for safe and effective treatment of four layers of skin - the epidermis, dermis, hypodermis and muscle – all via a single system. Practitioners can significantly rejuvenate most facial and body areas providing immediate and long lasting results in a convenient walk in-walk out procedure.
MaximusMED utilizes three advanced proprietary technologies: TriLipo RF, TriLipo DMA and TriFractional. TriLipo Radio Frequency Technology (RF) is used for wrinkle reduction, skin tightening, preventing wrinkles, cellulite treatment and localized fat reduction. TriLipo dynamic muscle activation (DMA) is used on the body to clear released fat and on the face to “lift” the SMAS (Superficial Muscular Aponeurotic System). TriFractional technology enables effective fractional skin resurfacing. These combined technologies complement each other to provide enhanced anti-aging and body contouring.
Mr. Newton Martins - General Manager of HV Comércio Importação e Exportação Ltda “We are proud to be the exclusive distributor of Pollogen’s products here in Brazil. Pollogen continually brings to the table the most innovative and clinically proven solutions. We are particularly pleased with the MaximusMED which enables us to offer advanced aesthetic treatments that achieve immediate and long-lasting dramatic results in just a few sessions”.
Mr. Amichai Bar-Nir, Pollogen’s CEO stated: Our longstanding partnership with HV Comércio Importação e Exportação Ltda has been crucial to Pollogen’s success in Brazil. We appreciate their enthusiasm for our products and value the evolving relationship between us."
“The ANVISA Medical Device Registration and Approval in Brazil provides us with a new opportunity to strengthen this strategic relationship while bringing the most cutting-edge anti-aging and body contouring solutions to the Brazilian market.”
“Maximus MED delivers impressive immediate and long-term results in safe, effective and convenient procedures. In other parts of the world aesthetic professionals testify that MaximusMED is the tool they have been waiting for and it has never been easier to treat a wide variety of aesthetic needs using a single system. We are confident that our users in Brazil will feel the same”.
Pollogen Ltd. is a global leader in the medical aesthetic market, providing professionals in over 60 countries with a wide variety of advanced aesthetic solutions to best serve their customers. Pollogen is the developer and manufacturer of five revolutionary technologies under the industry premier brand names OxyGeneo Technology™, Hybrid Energy Technology™, TriLipo, TriFractional™, TriPollar® and offers a full line of clinically-proven, safe and effective, non-invasive anti-aging facial and body contouring treatment platforms for a range of aesthetic applications including circumference reduction, cellulite reduction and skin tightening. For more information, visit http://www.pollogen.com.
Pollogen—Expect More: More Innovation, More Results, More Service.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10393242.htm